Trading Update

IXICO plc

("IXICO", the "Company" or the "Group")

Revenues anticipated to be ahead of expectations for the year ending 30 September 2025

17 July 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today provides a trading update for the financial year ending 30 September 2025.

The Company anticipates revenues to be at least £6.3 million, ahead of expectations and representing a 9% increase on 2024 revenues, thereby solidifying its stated return to growth. Further, it is expected that this revenue growth will continue into 2026, moving the Company towards medium term profitability.

IXICO has seen positive sales momentum driven by the implementation of the Company's 'Innovate Lead Scale' strategy, which has seen IXICO deliver scientific innovation while expanding commercial and geographic reach in key therapeutic areas and new market verticals. As indicated in the Half-year Trading Update on 16 April 2025, the Company has therefore increased the expected investment in 2025 to drive revenue growth in 2026 and beyond.

The Company expects to hold cash of at least £3.0 million at the end of the financial year.

Final results for the year ending 30 September 2025 will be announced in December 2025.

Bram Goorden, CEO of IXICO, said: "The Innovate Lead Scale strategy outlined during our capital raise has begun to deliver results. The positive momentum is a result of a team approach, executing with discipline to grow revenues, expand market share and diversify the neurological therapeutic areas we operate in. In addition, we are rapidly advancing our technology platform offering with new differentiated biomarker analytics products and applications fit for scale. This activity strengthens my belief that we will continue to build upon this year's commercial success and the progress we are making towards profitability in the medium term". 

Ends

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For further information please contact:

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.